The global Idiopathic intracranial hypertension therapeutics market size will grow by USD 15.34 million during 2019-2023, and the market’s growth momentum will accelerate throughout the forecast period.
This report provides a detailed analysis of the market by geography (Asia, Europe, North America, and ROW) and product (carbonic anhydrase inhibitors and other drug classes). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors, including AbbVie Inc., Astellas Pharma Inc., Cadila Healthcare Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
Market Overview
Browse TOC and LoE with selected illustrations and example pages from idiopathic intracranial hypertension therapeutics market report
Market Competitive Analysis
The idiopathic intracranial hypertension therapeutics market is fragmented, and the degree of fragmentation will increase during the forecast period. Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. are a few of the significant market participants. Although the accelerating market growth momentum will offer immense business opportunities, the limited patient pool will challenge the growth of the vendors. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
To help clients improve their market positions, this idiopathic intracranial hypertension therapeutics market forecast report provides a detailed analysis of the market leaders and offers information on the competencies and capacities of the companies. The report also covers details on the market’s competitive landscape and provides information on the products offered by various companies. This idiopathic intracranial hypertension therapeutics market analysis report also includes information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities.
This report provides information on the production, sustainability, and prospects of several leading idiopathic intracranial hypertension therapeutics companies, including:
- AbbVie Inc.
- Astellas Pharma, Inc.
- Cadila Healthcare Ltd.
- Johnson & Johnson Services Inc.
- Merck & Co., Inc.
- Mylan NV
- Pfizer Inc.
- Sanofi
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
Idiopathic Intracranial Hypertension Therapeutics Market: Segmentation by Region
For more insights on the Idiopathic intracranial hypertension therapeutics market share of various regions Request for a FREE sample now!
North America is one of the largest markets for idiopathic intracranial hypertension therapeutics. The presence of advanced healthcare infrastructure is accelerating business opportunities for vendors in the idiopathic intracranial hypertension therapeutics market in the region. The rising adoption of health insurance by patients is also increasing the demand for idiopathic intracranial hypertension therapeutics.
Almost 45% of the market’s growth will originate from North America during the forecast period. The rising risk factors of the condition and the growing awareness about the condition and the available treatment options will also fuel idiopathic intracranial hypertension therapeutics market growth in North America. Over the forecast period, market growth in this region will be faster than the growth of the market in other geographies.
Idiopathic Intracranial Hypertension Therapeutics Market: Segmentation by Product
Request for a FREE sample and Get more information on the market contribution of sales from various product segments
Acetazolamide, which is an inhibitor of carbonic anhydrase, gradually improves vision, decreases intracranial pressure and papilledema, and enhances the quality of patient life. Moreover, the drug is available in both generic and branded formulations. These factors are contributing to idiopathic intracranial hypertension therapeutics market growth in the carbonic anhydrase inhibitors segment.
The growth of the market in this segment will be faster than the market’s growth in the other segments. This report provides an accurate prediction of the contribution of all the segments to the growth of the idiopathic intracranial hypertension therapeutics market size.
Idiopathic Intracranial Hypertension Therapeutics Market: Key Drivers and Trends
There is an increasing prevalence of obesity across the globe, and this is subsequently leading to a rise in the incidence of idiopathic intracranial hypertension. With the growing prevalence of obesity among developed economies such as the US, there will be an increase in the patient pool for idiopathic intracranial hypertension over the forecast period. As idiopathic intracranial hypertension is associated with an increase in cardiovascular disorders, there will be a growing need for immediate therapeutic interventions.
- Several public and private organizations are organizing campaigns to create awareness about idiopathic intracranial hypertension.
- For instance, IIH UK, a forum managed by Rare Disease Europe (EURORDIS), helps patients with idiopathic intracranial hypertension in managing their condition.
- EURORDIS helps increase awareness about rare diseases and focuses on improving the health of patients with rare diseases. The organization conducts specialized social services and also facilitates R&D and healthcare policies.
- Such initiatives will lead to an increase in the awareness about idiopathic intracranial hypertension resulting in a rise in the adoption of therapeutics for the treatment of the indication.
- As a result of these factors, the market will register a CAGR of almost 3% over 2019-2023.
Request for a FREE sample now!
Idiopathic Intracranial Hypertension Therapeutics Market: Key Highlights of the Report for the Forecast Period 2019-2023
- CAGR of the market during the forecast period 2019-2023
- Detailed information on factors that will accelerate the growth of the idiopathic intracranial hypertension therapeutics market during the next five years
- Precise estimation of the global idiopathic intracranial hypertension therapeutics market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the idiopathic intracranial hypertension therapeutics industry Asia, Europe, North America, and ROW
- A thorough analysis of the market’s competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of idiopathic intracranial hypertension therapeutics vendors
We can help! Our analysts can customize this report to meet your requirements. Get in touch